A Real-world, Multicenter, 52-week Prospective Cohort Study to Capture the Reasons for Switch to Triple Combination Therapy and to Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe COPD Treated With Trixeo Aerosphere in Routine Care Settings in Greece.
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms TRIAENA
- Sponsors AstraZeneca
Most Recent Events
- 18 Apr 2025 Status changed from active, no longer recruiting to completed.
- 26 Apr 2024 Planned End Date changed from 30 Nov 2025 to 31 May 2025.
- 26 Apr 2024 Planned primary completion date changed from 30 Nov 2025 to 31 May 2025.